Stay updated on Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial

Sign up to get notified when there's something new on the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Revision entry v3.4.3 was added to the study record history, and revision v3.4.2 was removed.
    Difference
    0.1%
    Check dated 2026-03-10T02:48:31.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    22 days ago
    No Change Detected
  4. Check
    29 days ago
    Change Detected
    Summary
    The record history now includes a new revision v3.4.2 and removes v3.4.1 from the history. This update affects only the history log and not the study data.
    Difference
    0.1%
    Check dated 2026-02-16T15:33:23.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    The Record History shows a new revision entry (v3.4.1) added and the previous revision (v3.4.0) removed, reflecting an update to the study record's metadata.
    Difference
    0.1%
    Check dated 2026-02-09T09:50:59.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    The Record History page now shows a glossary toggle and uses green highlights for additions and red highlights for deletions, with the revision label updated from v3.3.4 to v3.4.0.
    Difference
    1%
    Check dated 2026-01-26T07:46:14.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    Record History now includes a new version entry v3.3.4 and removes the v3.3.3 entry. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-19T05:56:17.000Z thumbnail image
  8. Check
    85 days ago
    Change Detected
    Summary
    The Record History now includes a new revision entry (Revision: v3.3.3) and removes the HHS Vulnerability Disclosure and the previous Revision: v3.3.2 entries. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-12-21T21:34:27.000Z thumbnail image

Stay in the know with updates to Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page.